Validation of quantitative assessment of florbetaben PET scans as an adjunct to the visual assessment across 15 software methods

[1]  W. M. van der Flier,et al.  Quantification of [18F]florbetaben amyloid‐PET imaging in a mixed memory clinic population: The ABIDE project , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[2]  Barry A. Siegel,et al.  Quantitative analysis of 6,150 real‐world amyloid Positron Emission Tomography (PET) scans from the Imaging Dementia–Evidence for Amyloid Scanning (IDEAS) study , 2022, Alzheimer's & Dementia.

[3]  W. M. van der Flier,et al.  Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline , 2022, Nature Medicine.

[4]  M. Mintun,et al.  Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes , 2022, JAMA neurology.

[5]  F. Barkhof,et al.  Quantification of amyloid PET for future clinical use: a state-of-the-art review , 2022, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  S. Seo,et al.  Finding the optimal cutoff value for amyloid β positivity using the iterative outlier method and concordance rate , 2021 .

[7]  J. Molinuevo,et al.  A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  C. Rowe,et al.  Early detection of amyloid load using 18F-florbetaben PET , 2021, Alzheimer's research & therapy.

[9]  K. Miwa,et al.  Quantitative Evaluation of 18F-Flutemetamol PET in Patients With Cognitive Impairment and Suspected Alzheimer's Disease: A Multicenter Study , 2021, Frontiers in Neurology.

[10]  J. Molinuevo,et al.  Converging evidence for a “gray‐zone” of amyloid burden and its relevance , 2020 .

[11]  Vincent Doré,et al.  Non-negative matrix factorisation improves Centiloid robustness in longitudinal studies , 2020, NeuroImage.

[12]  D. Berry,et al.  A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody , 2020, Alzheimer's Research & Therapy.

[13]  G. Cheon,et al.  Visual interpretation of [18F]Florbetaben PET supported by deep learning–based estimation of amyloid burden , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  A. Ciarmiello,et al.  Impact of Tracer Retention Levels on Visual Analysis of Cerebral [18f]- Florbetaben pet Images. , 2020, Current radiopharmaceuticals.

[15]  R. Lhommel,et al.  Defining a Centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [18F] flutemetamol amyloid PET study , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  Young Hee Jung,et al.  Concordance in detecting amyloid positivity between 18F-florbetaben and 18F-flutemetamol amyloid PET using quantitative and qualitative assessments , 2020, Scientific Reports.

[17]  Mark E. Schmidt,et al.  Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study , 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[18]  Elizabeth C Mormino,et al.  Neuroanatomical spread of amyloid β and tau in Alzheimer’s disease: implications for primary prevention , 2020, Brain communications.

[19]  Jun Pyo Kim,et al.  Staging and quantification of florbetaben PET images using machine learning: impact of predicted regional cortical tracer uptake and amyloid stage on clinical outcomes , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  G. Farrar,et al.  The Spatial-Temporal Ordering of Amyloid Pathology and Opportunities for PET Imaging , 2019, Journal of Nuclear Medicine.

[21]  M. Andjelkovic,et al.  Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis , 2019, Alzheimer's Research & Therapy.

[22]  D. Holtzman,et al.  Alzheimer Disease: An Update on Pathobiology and Treatment Strategies , 2019, Cell.

[23]  O. Hansson,et al.  Staging β-Amyloid Pathology With Amyloid Positron Emission Tomography. , 2019, JAMA neurology.

[24]  C. Rowe,et al.  Comparison of 18F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL® approaches: Validation against histopathology , 2019, Alzheimer's & Dementia.

[25]  K. Blennow,et al.  Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers , 2019, Alzheimer's Research & Therapy.

[26]  C. Jack,et al.  Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology , 2018, Alzheimer's & Dementia.

[27]  R. Gunn,et al.  Amyloid Load: A More Sensitive Biomarker for Amyloid Imaging , 2018, The Journal of Nuclear Medicine.

[28]  Olivier Salvado,et al.  Implementing the centiloid transformation for 11C-PiB and β-amyloid 18F-PET tracers using CapAIBL , 2018, NeuroImage.

[29]  J. Dukart,et al.  Rate of β-amyloid accumulation varies with baseline amyloid burden: Implications for anti-amyloid drug trials , 2018, Alzheimer's & Dementia.

[30]  Jens Sörensen,et al.  Spatial Normalization of 18F-Flutemetamol PET Images Using an Adaptive Principal-Component Template , 2018, The Journal of Nuclear Medicine.

[31]  Chengjie Xiong,et al.  Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies , 2018, NeuroImage: Clinical.

[32]  D. Sharp,et al.  Spatiotemporal Distribution of β-Amyloid in Alzheimer Disease Is the Result of Heterogeneous Regional Carrying Capacities , 2017, The Journal of Nuclear Medicine.

[33]  Vincent Doré,et al.  18F-Florbetaben PET beta-amyloid binding expressed in Centiloids , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[34]  John Seibyl,et al.  Optimized classification of 18F-Florbetaben PET scans as positive and negative using an SUVR quantitative approach and comparison to visual assessment , 2017, NeuroImage: Clinical.

[35]  J. Seibyl,et al.  Yes we can analyse amyloid images - Now What? , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[36]  M. Mintun,et al.  Quantitation of PET signal as an adjunct to visual interpretation of florbetapir imaging , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[37]  John Seibyl,et al.  Impact of Training Method on the Robustness of the Visual Assessment of 18F-Florbetaben PET Scans: Results from a Phase-3 Study , 2016, The Journal of Nuclear Medicine.

[38]  Chloe Hutton,et al.  Classification of amyloid status using machine learning with histograms of oriented 3D gradients , 2016, NeuroImage: Clinical.

[39]  Takamichi Murakami,et al.  Performance of 11C-Pittsburgh Compound B PET Binding Potential Images in the Detection of Amyloid Deposits on Equivocal Static Images , 2015, The Journal of Nuclear Medicine.

[40]  John Seibyl,et al.  Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study , 2015, Alzheimer's & Dementia.

[41]  Ranjan Duara,et al.  Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. , 2015, JAMA neurology.

[42]  C. Rowe,et al.  Comparison of MR-less PiB SUVR quantification methods , 2015, Neurobiology of Aging.

[43]  Robert A. Koeppe,et al.  The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET , 2015, Alzheimer's & Dementia.

[44]  John Seibyl,et al.  Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[45]  Olivier Salvado,et al.  MR-Less Surface-Based Amyloid Assessment Based on 11C PiB PET , 2014, PloS one.

[46]  Elizabeth C Mormino,et al.  Not quite PIB-positive, not quite PIB-negative: Slight PIB elevations in elderly normal control subjects are biologically relevant , 2012, NeuroImage.